Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atomoxetine - Eli Lilly and Company

Next Previous
Drug Profile

Atomoxetine - Eli Lilly and Company

Alternative Names: Atomoxetine hydrochloride; LY 139603; Strattera; Tomoxetine; Tomoxetine hydrochloride

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Johns Hopkins University
  • Class Antidementias; Antidepressants; Antiparkinsonians; Behavioural disorder therapies; Propylamines
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Alzheimer's disease; Major depressive disorder; Parkinson's disease

Most Recent Events

  • 06 Jan 2020 Discontinued - Phase-III for Parkinson's disease in USA (PO) (Eli Lilly and Company website, January 2020)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder(In volunteers) in Japan (PO, Liquid)
  • 07 Aug 2015 No recent reports on development identified - Phase-III for Attention-deficit hyperactivity disorder (In adults) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top